Kentucky Hemp Conference Underscores Current Industry Risks

On Thursday last week, an association representing Kentucky’s hemp industry held a conference in Murray. The gathering involved hemp farmers, processors, and regulators, and it highlighted the continuing regulatory uncertainty that’s been facing the hemp industry.

Hemp became legal after the 2018 Farm Bill distinguished cannabis with minuscule levels of THC, less than 0.3%, giving farmers the green light to farm it under state and tribal programs. However, most states have different laws concerning hemp and its extracts.

Some allow it, some don’t, while some don’t even have hemp programs. This patchwork of legislation was one of the main issues covered during the Kentucky Hemp Industries Association Holiday Conference and Tradeshow.

The conference was graced with a variety of speakers, including regional lawyers offering insight on current and future hemp regulations, university professors discussing hemp’s chemical composition and industry advocates with expert marketing tips for hemp-derived products.

According to Bob Pearce, one of the Professors from the University of Kentucky College of Agriculture, Food and Environment, there is a lot of financial risk surrounding how the federal government will regulate hemp-derived products, primarily CBD (Cannabidiol).

Cannabidiol is one of the major cannabinoids found in the cannabis plant, and as per the 2018 Farm Bill, it is legal as long as it was derived from hemp (cannabis with less than 0.3% THC. It is the chemical responsible for cannabis’ infamous high).

CBD is an insanely potent natural medicine with a plethora of applications. Users have claimed the chemical gave them relief from insomnia, chronic pain, and high blood pressure, among other ailments. Still, most of the evidence backing these claims up is anecdotal.

The only instance where a medical claim has been researched and tested is Epidiolex. The FDA-approved drug is made from CBD, and it’s used to treat seizures in two rare pediatric epilepsies, Dravet Syndrome and Lennox-Gastaut Syndrome.

The FDA has made it clear that CBD sellers shouldn’t advertise their products as therapeutic, even going so far as to send warning letters to several companies accused of doing so.

Currently, the agency is working on CBD regulations, specifically whether the hemp extract can be classified as a nutritional supplement that could be added to food products.

“If you’re well invested in this process and that ruling goes opposite of the way you think it’s going to go, you could be all out of that investment. So for growers, I always say don’t get in over your head,” says Pearce.

Experts see the concerns discussed during this conference as issues that plague the entire industry, including sector players like Marijuana Company of America Inc. (OTCQB: MCOA) and No Borders Inc. (OTC: NBDR), who long for a stable industry that has clear regulations.

About HempWire

HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/Disclaimer

Do you have a questions or are you interested in working with HW? Ask our Editor

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net

HempWire is part of the InvestorBrandNetwork.

Archives

Select A Month

HempWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722